AR and prostate carcinoma: They demonstrated that CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases AR- and c-Myc–regulated gene expression.331 A phase I/II study to assess the safety, tolerability, pharmacokinetics and biological activity of CCS1477 in patients with metastatic castration-resistant prostate cancer (mCRPC) or advanced solid tumors was started in 2018.